Market Overview:
The global epalrestat (CAS 82159-09-9) market is expected to register a CAGR of xx% during the forecast period 2018–2030. The market growth can be attributed to the increasing prevalence of diabetic retinopathy, rising geriatric population, and growing demand for better treatment options. Based on type, the global epalrestat (CAS 82159-09-9) market is segmented into 5mg/tablets, 10mg/tablets, and 50mg/tablets. The 10mg/tablet segment is expected to register the highest CAGR during the forecast period. This can be attributed to its higher efficacy as compared to other dosage forms and growing demand for better treatment options. Based on application, the global epalrestat (CAS 82159-09-9) market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to account for a larger share of the global epalrestat (CAS 82159-09-9) market in 2018 owing to rising number of patients with diabetic retinopathy seeking medical attention in hospitals.
 Industry Outlook.svg)
Product Definition:
Epalrestat is a selective aldose reductase inhibitor that has been used in the treatment of diabetic neuropathy.
5mg/Tablets:
5mg/Tablets, it's usage.
The mechanism of action of epalrestat is still unknown to many people. The drug has been reported to have antianginal properties but these were not confirmed when tested in clinical trials.
10mg/Tablets:
10mg/Tablets is a white to off-white solid powder with odor like talc. It is used as an excipient in the manufacturing of various pharmaceuticals including epalrestat, which is a topical drug used for the treatment of diabetic macular edema and retinopathy. The 10 mg/tablet formulation contains approximately 0.3 mg actual drug substance and rest are filler ingredients accounting for 90% of its weight.
Application Insights:
Based on application, the global epalrestat market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The online pharmacy segment is anticipated to exhibit the highest CAGR of XX% during the forecast period. Increasing internet accessibility has enabled people with diagnosed heart conditions to purchase medicines from their homes without visiting medical stores or clinics. This trend has positively influenced demand for epalrestat in this region.
The hospital pharmacy application segment accounted for a significant share of over 40% in 2017 owing to rising awareness about available treatment options among patients and increasing government initiatives towards reducing healthcare expenditure are some factors responsible for its dominance during the forecast period. However, decreasing prices of generic drugs have started challenging margins of hospitals and pharmacies which may result in reduced consumption by 2030 unless corrective measures are taken by manufacturers or governments restrict price cuts below allowable levels.
Regional Analysis:
North America was the largest regional market for epalrestat in 2017. The growth of this region is attributed to increasing prevalence of diabetes and cancer coupled with rising healthcare expenditure in the U.S., which is one of the highest among all countries worldwide. Moreover, availability of branded drugs at higher prices in this region has encouraged people to opt for alternative therapies such as acupuncture, thereby boosting product demand over the forecast period.
Asia Pacific is expected to be one of fastest growing regions owing to presence of a large number acupuncturists and other practitioners who use epalrestat on a regular basis along with its low cost as compared to western medicines used for same purposes. In addition, increasing awareness about traditional Chinese medicine coupled with rising disposable income will drive regional market growth during the forecast period from 2018-2030 (USD X million).
Growth Factors:
- Increasing incidence of diabetic neuropathy
- Growing geriatric population
- Rising awareness about the benefits of Epalrestat (CAS 82159-09-9) therapy
- Technological advancements in the field of diabetes management
- Availability of generic versions of Epalrestat (CAS 82159-09-9)
Scope Of The Report
Report Attributes
Report Details
Report Title
Epalrestat (CAS 82159-09-9) Market Research Report
By Type
5mg/Tablets, 10mg/Tablets, 50mg/Tablets
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Unit Pharma, Yangtze River Pharma, DYNE Pharma, Zydus Cadila, Exeltis, Micro Labs, Zauba Corp, Schem, Vivid Biotek
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Epalrestat (CAS 82159-09-9) Market Report Segments:
The global Epalrestat (CAS 82159-09-9) market is segmented on the basis of:
Types
5mg/Tablets, 10mg/Tablets, 50mg/Tablets
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Unit Pharma
- Yangtze River Pharma
- DYNE Pharma
- Zydus Cadila
- Exeltis
- Micro Labs
- Zauba Corp
- Schem
- Vivid Biotek
 Market Overview.svg)
Highlights of The Epalrestat (CAS 82159-09-9) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5mg/Tablets
- 10mg/Tablets
- 50mg/Tablets
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Epalrestat (CAS 82159-09-9) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Epalrestat is a drug that is used to treat psoriasis. It works by reducing the number of skin cells in the skin.
Some of the major companies in the epalrestat (cas 82159-09-9) market are Unit Pharma, Yangtze River Pharma, DYNE Pharma, Zydus Cadila, Exeltis, Micro Labs, Zauba Corp, Schem, Vivid Biotek.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Epalrestat (CAS 82159-09-9) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Epalrestat (CAS 82159-09-9) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Epalrestat (CAS 82159-09-9) Market - Supply Chain
4.5. Global Epalrestat (CAS 82159-09-9) Market Forecast
4.5.1. Epalrestat (CAS 82159-09-9) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Epalrestat (CAS 82159-09-9) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Epalrestat (CAS 82159-09-9) Market Absolute $ Opportunity
5. Global Epalrestat (CAS 82159-09-9) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Type
5.3.1. 5mg/Tablets
5.3.2. 10mg/Tablets
5.3.3. 50mg/Tablets
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Epalrestat (CAS 82159-09-9) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Epalrestat (CAS 82159-09-9) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Epalrestat (CAS 82159-09-9) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Epalrestat (CAS 82159-09-9) Demand Share Forecast, 2019-2026
9. North America Epalrestat (CAS 82159-09-9) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Type
9.7.1. 5mg/Tablets
9.7.2. 10mg/Tablets
9.7.3. 50mg/Tablets
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Epalrestat (CAS 82159-09-9) Demand Share Forecast, 2019-2026
10. Latin America Epalrestat (CAS 82159-09-9) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Type
10.7.1. 5mg/Tablets
10.7.2. 10mg/Tablets
10.7.3. 50mg/Tablets
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Epalrestat (CAS 82159-09-9) Demand Share Forecast, 2019-2026
11. Europe Epalrestat (CAS 82159-09-9) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Type
11.7.1. 5mg/Tablets
11.7.2. 10mg/Tablets
11.7.3. 50mg/Tablets
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Epalrestat (CAS 82159-09-9) Demand Share, 2019-2026
12. Asia Pacific Epalrestat (CAS 82159-09-9) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Type
12.7.1. 5mg/Tablets
12.7.2. 10mg/Tablets
12.7.3. 50mg/Tablets
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Epalrestat (CAS 82159-09-9) Demand Share, 2019-2026
13. Middle East & Africa Epalrestat (CAS 82159-09-9) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Epalrestat (CAS 82159-09-9) Market Size and Volume Forecast by Type
13.7.1. 5mg/Tablets
13.7.2. 10mg/Tablets
13.7.3. 50mg/Tablets
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Epalrestat (CAS 82159-09-9) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Epalrestat (CAS 82159-09-9) Market: Market Share Analysis
14.2. Epalrestat (CAS 82159-09-9) Distributors and Customers
14.3. Epalrestat (CAS 82159-09-9) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Unit Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Yangtze River Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. DYNE Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Zydus Cadila
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Exeltis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Micro Labs
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Zauba Corp
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Schem
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Vivid Biotek
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
